ArticleJAMA dermatology2020
Assessment of Overall and Specific Cancer Risks in Patients With Hidradenitis Suppurativa.
Article in JAMA dermatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Risk of Cancer in Patients with Hidradenitis Suppurativa: A Systematic Review and Meta-analysis.Dermatology and therapy · 2026Pooled it
- A state-of-the-art systematic review of cancer in hidradenitis suppurativa.Annals of medicine · 2024Pooled it
- Incidence of Skin Cancer in Patients With Chronic Inflammatory Cutaneous Diseases on Targeted Therapies: A Systematic Review and Meta-Analysis of Observational Studies.Frontiers in oncology · 2021Pooled it
- Diffuse CD30-Positive Cutaneous Infiltrate in a Clinically Suspected Hidradenitis Suppurativa Lesion: Histopathologic and Diagnostic Challenges.Journal of cutaneous pathology · 2026Article
- Causal relationship and potential common pathogenic mechanisms between hidradenitis suppurativa and related cancer.Discover oncology · 2025Article
- Identification and Validation of Hub Genes in Hidradenitis Suppurativa.Clinical, cosmetic and investigational dermatology · 2025Article
- Hidradenitis Suppurativa Cancer Risk: A Review of the Literature.Clinical, cosmetic and investigational dermatology · 2025Review
- Investigating the association between hidradenitis suppurativa and malignancy risks: a systematic review.Archives of dermatological research · 2024Article
- Deregulated Long Non-Coding RNAs (lncRNA) as Promising Biomarkers in Hidradenitis Suppurativa.Journal of clinical medicine · 2024Article
- Autoimmune, Autoinflammatory Disease and Cutaneous Malignancy Associations with Hidradenitis Suppurativa: A Cross-Sectional Study.American journal of clinical dermatology · 2024Article
- Increased cancer incidence among patients with hidradenitis suppurativa - a Danish nationwide register study 1977-2017.Acta oncologica (Stockholm, Sweden) · 2024Article
- Refractory Hidradenitis Suppurativa: A Diagnosis to Consider.GE Portuguese journal of gastroenterology · 2024Article
- Unlocking the Mechanisms of Hidradenitis Suppurativa: Inflammation and miRNA Insights.Clinical, cosmetic and investigational dermatology · 2024Review
- Integrated bioinformatics combined with machine learning to analyze shared biomarkers and pathways in psoriasis and cervical squamous cell carcinoma.Frontiers in immunology · 2024Article
- Hidradenocarcinoma in a Crohn's patient on ustekinumab: A case report.SAGE open medical case reports · 2024Article
- Inborn Errors of Immunity in Hidradenitis Suppurativa Pathogenesis and Disease Burden.Journal of clinical immunology · 2023Review
- The Development of Systemic Inflammatory Diseases in Hidradenitis Suppurativa.Diagnostics (Basel, Switzerland) · 2023Review
- Obstacles to Early Diagnosis and Treatment of Hidradenitis Suppurativa: Current Perspectives on Improving Clinical Management.Clinical, cosmetic and investigational dermatology · 2023Review
- Association of hidradenitis suppurativa and liver disease: A systematic review and meta-analysis.JAAD international · 2022Article
- Phenotype Algorithms to Identify Hidradenitis Suppurativa Using Real-World Data: Development and Validation Study.JMIR dermatology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Large population-based studies investigating the risks of overall and specific cancers among patients with hidradenitis suppurativa (HS) are limited. Objective: To assess the overall and specific cancer risks in patients with HS compared with the risks in patients without HS in the Republic of Korea. Design, Setting, and Participants: A nationwide population-based cohort study, using the Korean Health Insurance Review and Assessment Service database was conducted over a 2-year period from January 1, 2007, to December 31, 2008. Individuals in the control group who were never diagnosed with HS or cancer during the washout period were randomly extracted and matched by age, sex, index year, and insurance type at a case-control ratio of 1:8, and patients with newly diagnosed HS between January 1, 2009, and December 31, 2017, were included. Follow-up data on incident cancer from January 1, 2009, to December 31, 2018, were included. Main Outcomes and Measures: The overall and specific cancer incidence rates were calculated per 100 000 person-years in patients with HS and in the matched control cohort. The risk for cancers was assessed by multivariable Cox regression models in patients with HS compared with the matched control cohort. Results: In total, 22 468 patients with HS and 179 734 matched controls were included in the study. The mean (SD) age was 33.63 (17.61) years and 63.7% of the participants in both groups were male. The adjusted hazard ratio (aHR) of overall cancer in patients with HS was 1.28 (95% CI, 1.15-1.42). Patients with HS had significantly higher risk for Hodgkin lymphoma (aHR, 5.08; 95% CI, 1.21-21.36), oral cavity and pharyngeal cancer (aHR, 3.10; 95% CI, 1.60-6.02), central nervous system cancer (aHR, 2.40; 95% CI, 1.22-4.70), nonmelanoma skin cancer (HR, 2.06; 95% CI, 1.12-3.79), prostate cancer (aHR, 2.05; 95% CI, 1.30-3.24), and colorectal cancer (aHR, 1.45; 95% CI, 1.09-1.93). Conclusions and Relevance: In this study, HS appeared to be associated with a significantly increased risk of overall cancer as well as several specific cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.